Analysis on whether brivaracetam can be reimbursed by medical insurance and policy interpretation

Brivaracetam (brivaracetam) is an anti-epileptic drug used to treat epilepsy. It has attracted the attention of patients and doctors because of its good efficacy and tolerability. However, Brivaracetam has not yet been officially launched in China, which directly affects the possibility of medical insurance reimbursement. Since the drug is not included in the national drug catalog, the domestic medical insurance system is temporarily unable to cover the cost of the drug.

Medical insurance reimbursement usually requires drugs to be approved for marketing by the State Food and Drug Administration, included in the national medical insurance catalog, and pass relevant review procedures. At present, Brivaracetam has not completed the domestic marketing process and has not yet entered the scope of medical insurance, resulting in domestic patients being unable to reduce the burden of medication through medical insurance reimbursement. If patients want to use Brivaracetam, they can only purchase it through formal overseas channels and cannot enjoy medical insurance support.

It is reported that the original version of Brivaracetam has been launched in overseas markets, with the specifications of 50mg*60 tablets, and the price is about 4000 multiple RMB. Relatively high drug prices and the inability to be reimbursed by medical insurance have put greater financial pressure on patients. When patients choose to purchase drugs overseas, they need to pay attention to the legality and safety of the drug sources and avoid buying counterfeit or inferior products.

To sum up, Brivaracetam is not yet available in the country, and the medical insurance system is temporarily unable to cover its costs. If patients have usage needs, they should rationally plan drug purchase channels under the guidance of doctors. At the same time, they should pay attention to the dynamic changes in domestic listing and medical insurance policies in the future, and look forward to obtaining more convenient and economical drug protection through legal channels in the future.

Reference materials:https://www.drugs.com/